The nPulse Vybrance System uses Nanosecond Pulsed Field Ablation (nsPFA) energy to induce Regulated Cell Death in cells while minimizing damage to surrounding tissue, featuring the nPulse Console and nPulse Vybrance Percutaneous Electrodes.
The nsPFA System uses Nanosecond Pulsed Field Ablation (nsPFA) technology to ablate cells during electrophysiology procedures while minimizing damage to surrounding tissue, featuring the nsPFA Console and nsPFA 360 Catheter.
The nsPFA System uses Nanosecond Pulsed Field Ablation (nsPFA) technology to ablate cells during cardiac surgery while minimizing damage to surrounding tissue, featuring the nsPFA Console and nsPFA Cardiac Clamp.
Pulse Biosciences invented and exclusively owns Nanosecond Pulsed Field Ablation (nsPFA) technology, which delivers nanosecond electrical pulses to clear cells without thermal damage while preserving adjacent tissue.
Pulse Biosciences develops its patented nPulse technology for healthcare applications, including ablation of soft tissue, benign thyroid tumors, and cardiac procedures like atrial fibrillation.
Pulse Biosciences maintains high standards of business conduct and ethics, outlining principles in its Code of Business Conduct to guide employee behavior and deter wrongdoing.